New treatments for parkinson's disease are in the clinical trial pipeline, with some therapies reportedly entering the final stages of trials. Various organizations, including the michael j fox foundation, are supporting the development of these treatments, with some focusing on specific targets such as alpha synuclein. The pipeline includes a range of emerging options, including cell therapeutics, with some outlets providing retrospective analyses and previews of trials to watch.